|
|
|
|
|
|
|
Aclaris Therapeutics Inc. (ACRS)
|
|
15.17 -0.26 (-1.69%)
|
09-21 16:00
|
|
Open:
|
15.47
|
Pre. Close:
|
15.43
|
|
High:
|
15.48
|
Low:
|
14.91
|
|
Volume:
|
196,205
|
Market Cap:
|
470M
|
|
|
|
Stock Price Prediction (Update at 5:00pm est.)
|
|
If
tomorrow:
|
Open
lower
|
Open
higher
|
|
High:
|
15.51 - 15.598
|
15.598 - 15.694
|
|
Low:
|
14.667 - 14.763
|
14.763 - 14.867
|
|
Close:
|
14.986 - 15.156
|
15.156 - 15.339
|
|
|
|
Technical analysis (as of: 2018-09-21 4:23:02 PM)
|
|
Overall:
|
 
|
|
Stoxline rating system posted a NEUTRAL today, downgraded from higher rating. This stock seems to stay at current move trend, but it could change at anytime. So it is not a good time to buy or sell, stay at where you are until next BUY or SELL signal.
|
|
Target:
|
Six months: 18.20 One year: 19.26
|
|
Support:
|
Support1: 14.11 Support2: 11.74
|
|
Resistance:
|
Resistance1:
15.58 Resistance2: 16.49
|
|
Pivot:
|
15.30 
|
|
Moving Averages:
|
MA(5): 15.22 MA(20): 15.28
MA(100): 18.04 MA(250): 20.47
|
|
MACD:
|
MACD(12,26):
-0.39 Signal(12,26,9): -0.51
|
|
%K %D:
|
%K(14,3): 39.50 %D(3): 38.93
|
|
RSI:
|
RSI(14): 44.51
|
|
52-Week:
|
High: 28.62
Low: 14.115 Change(%): -41.7
|
|
Average Vol(K):
|
3-Month: 23732
10-Days 16482
|
|
|
|
|
|
★
Strong Sell
★★
Sell ★★★
Neutral
★★★★
Buy
★★★★★
Strong Buy
|
|
|
Price, moving averages and
Bollinger Bands
|
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.ACRS has closed above bottom band by 38.7%. Bollinger Bands are 54.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to ACRS's normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
|
|
|
Headline News
|
|
2018-08-03T14:29:15-04:00
Aclaris Therapeutics' (ACRS) CEO Neal Walker on Q2 2018 Results - Earnings Call Transcript
2018-08-03T08:33:00-04:00
Aclaris reports Q2 results
2018-08-03T07:03:24-04:00
Aclaris Therapeutics beats by $0.08, beats on revenue
|
|
|
Financial Analysis
|
|
Growth
|
|
|
Growth measures the growth of both a company's revenue
and net income. it tells investors how fast a company is growing.
|
|
Profitability
|
|
|
Profitability measures a company’s ability to
generate earnings as compared to its expenses
and other relevant costs.
|
|
Solvency
|
|
|
Solvency measures a company's ability to meet its long-term debts.
Acceptable solvency ratios will vary from industry to industry.
|
|
Efficiency
|
|
|
Efficiency measures the strength of a company's return on invested capital.
It can identify business that are better managed or not.
|
|
Click here to get more fundamental analysis.
|
|
